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Objectives: To investigate bladder function of spinal cord injury (SCI) patients in the 
long-term since morbidity and mortality of SCI patients are closely related to bladder 
function but long-term data are scarce. 
Subjects/patients and methods: A consecutive series of 246 SCI patients with 
neurogenic lower urinary tract dysfunction (NLUTD) was evaluated at a single 
university spinal cord injury center in a longitudinal study. Patients were prospectively 
evaluated since 2010 and compared retrospectively to the eldest urodynamic 
examination which could be found in the archive with a mean follow-up period of 6 
years. 
Results: Mean age at injury and mean duration of lesion were 51 ± 14 and 17 ± 10 
years, respectively.55% (163/246) of the patients had a thoracic SCI and 21% 
(51/246), 18% (44/246) and 2% (6/246) had a cervical, lumbar and sacral lesion, 
respectively. In the most current (and eldest examination), most patients 147/246 
(131/246) relied on intermittent self-catheterization, 65/246 (89/246) voided 
spontaneously and 49/246 (43/246) had an indwelling catheter. 147/246 (168/246) 
patients had no urological medication, the remaining 99/246 (78/246) were under 
antimuscarinics or alpha-blockers and/or underwent regular botulinum neurotoxin 
type A (BoNTA) intra detrusor injections. Mean maximum cystometric capacity, 
maximum detrusor pressure during the storage phase and bladder compliance were 
650 mL (440mL), 34 cmH2O (25cmH2O) and 95 mL/cmH2O (55mL/cmH2O), 
respectively. Detrusor overactivity was found in 130/246 (59/246) and vesico-uretero-
renal reflux (grade I or II) in 12/246 (11/246) patients (unilateral in 5 (9), bilateral in 7 
(2)). 
Conclusions: Most of our regularly followed patients with NLUTD due to SCI for a 
mean of 17 years had normal maximum cystometric capacity, maximum detrusor 
pressure during the storage phase, and bladder compliance. Vesico-uretero-renal 
reflux was quite rare and low grade. Thus, regular follow-up with urodynamic 
investigation allowing for individual bladder management seems beneficial warranting 







Spinal cord injury (SCI) often causes neurogenic lower urinary tract dysfunction 
(NLUTD)(1). Neuro-urological care aims preservation or improvement of upper 
urinary tract function, control of urinary tract infection, and maintenance of a low-
pressure bladder that is both continent and capable of emptying completely(2). 
These goals are ideally achieved without an indwelling catheter or a stoma, and in a 
manner that is socially and vocationally acceptable to the patient avoiding 
complications such as recurrent urinary tract infections, urethral strictures, calculus 
disease, hydronephrosis, and renal failure(2). In the past, renal disease was 
responsible for almost 50% of deaths in SCI patients(3). Fortunately, this changed 
dramatically. Nowadays, urinary disease accounts for only about 13% of deaths in 
SCI patients whereas pneumonia, influenza, non-urinary tract septicemia, cancer, 
and ischemic heart disease are more common causes of death(4, 5). The 
introduction of intermittent self-catheterization (ISC) combined with antimuscarinic 
treatment and the use of regular urodynamic investigations revolutionized the care of 
SCI patients(6-8). Thus, adequate function of the lower urinary tract is essential to 
prevent morbidity and mortality in SCI patients, but publications investigating bladder 
function of these patients in the long-term are scarce. We therefore assessed the 
long-term data of a strictly urodynamic-based treatment regime in patients with 




Patients & Methods 
 
Ethics statement 
This study was approved by the local ethics committee (i.e. the Kantonale 
Ethikkommission Zürich, Switzerland, study identification number: EK 2010-0207/01) 
and registered with ClinicalTrials.gov (study registration number: NCT01297660). All 
participants gave written informed consent. 
 
Patients 
From January 2010 to June 2014, 246 SCI patients were prospectively evaluated at 
the Spinal Cord Injury Center, Balgrist University Hospital, Zürich. The obtained data 
of the current examination was compared retrospectively to the eldest urologic 
examination including an urodynamic examination which could be found in the 
archive. Inclusion criteria were NLUTD due to SCI and duration of SCI of at least 5 
years. Pregnant and breast feeding women and patients <18 years old at last 
evaluation were excluded. 
All methods, definitions, and units are according to the standards recommended by 
the International Continence Society(9). 
 
Neuro-urological evaluation 
Neuro-urological evaluation consisted of medical history, clinical examination, 
urinalysis, urine culture, urinary tract ultrasound, and video-urodynamic investigation 
including pelvic floor electromyography(1). Video-urodynamics were performed using 
a multichannel system according to good urodynamic practices standard procedure 
recommended by the International Continence Society(10, 11). Patients were 
urodynamically investigated in a sitting position whenever possible. The bladder was 
filled with a 36°C mixture of 0.9% sodium chloride solution and contrast medium at a 
speed of 20mL/min. 
 
Outcome measures 
Primary outcome measures were urodynamic parameters including maximum 
cystometric capacity, maximum detrusor pressure during the storage phase, bladder 
compliance, detrusor overactivity, and detrusor leak point pressure. Secondary 
outcome measures were vesico-uretero-renal reflux (VUR) and urinary tract 
ultrasound. Normal renal parenchyma thickness was defined as >12mm, determined 
by the coronal measure of the distance between the renal sinus/parenchyma 
interface and the renal surface(12). 
Tertiary outcome measure was the urinary continence status including the pads used 





Data were approximately normal distributed and presented as mean  standard 
deviation (SD). Comparing related and unrelated samples, the paired and unpaired t 
test was used. The value of significance was considered at p<0.05. Statistical 







Of the 246 patients enrolled almost four out of five were men. The biggest group of 
patients suffered from thoracic spinal cord injury and ASIA impairment score grade A, 
i.e. complete lesion with no sensory or motor function preserved (http://www.asia-
spinalinjury.org).Mean duration since SCI to most current examination was 17 ± 10 
and mean age of patients at that time was 51 ± 14 years. (for detailed patient 
characteristics please see Table 1)  
The mean follow up time between the most current and most eldest examination was 
6 ± 3 years. 
The most common type of bladder emptying is the clean intermittent self-
catheterization (ISK). The total number of patients treated with indwelling catheters 
remains among the age of SCI about the same with one out of five. Whereas 
spontaneous voiding declined by 10% (24 patients). (for detailed bladder emptying 
characteristics please see Table 2) At the most current examination 80 patients 
(33%) suffered from urinary incontinence. Of these, 27 (11%) persons used one pad 
per day and 22 patients required 2 or more pads per 24 hours. 
The numbers of patients with urological treatments remained about the same among 
the years (details in Table 3). Two out of three patients have no urological 
medication, one out of four is treated by antimuscarinics and one third of patients 
receives Botulinum A toxin (BoNTA) injections into the detrusor. This rate increased 
impressive by 51 patients (264%). 
Mean maximum cystometric capacity, mean maximum detrusor pressure during the 
storage phase, and mean bladder compliance were within the normal range(see 
details in Table 4). Video-urodynamic findings changed over the years significant, but 
remained all within the normal range (see details in Table 4). Mean maximum 
cystometric capacity and mean maximum detrusor pressure during storage phase 
increased by 210 mL and 9 cmH2O, respectively. Mean compliance rose by 40 
mL/cmH2O while mean detrusor leak point pressure decreased by 25 cmH2O. 
Addidtional 71 patients (29%) suffered on the most currend examination from 
detrusor overactivity, what means an increase by 220%. Furthermore, detrusor 
overactivity related to incontinence increased by 13% (33 patients). 
The total number of patients suffering from vesicoureterorenal reflux remained about 
the same (details in Table 5). However the number of unilateral reflux drops by 4 
patients, while the number of patients with bilateral reflux rose by 7 patients. In 
addition there was one case with a unilateral reflux grade IV and one with a bilateral 









Most of our regularly followed patients suffering from NLUTD due to SCI for a mean 
of 17 ± 10 years had normal maximum cystometric capacity, maximum detrusor 
pressure during the storage phase, and bladder compliance. VUR was quite rare and 
low grade. On the most current examination, less patients used spontaneous voiding 
and relied instead on clean intermittent self-catheterization or indwelling catheter 
instead.  
The use of urological medication in general increased, in particular the injections of 
BoNTA into the detrusor is increased 2.6 folds. Nevertheless Antimuscarinics were 
slightly less frequently used. Mean maximum detrusor pressure during storage rose 
and more patients suffered from detrusor overactivity. Considering the findings of the 
present study, regular follow-up including urodynamic investigations seems 
warranted since this allows for an individual bladder management preserving / 
improving lower and upper urinary tract function. 
 
Findings in the context of existing evidence 
Morbidity and mortality of SCI patients are closely related to bladder function. 
Elevated bladder pressure during the storage phase, either due to low-compliance 
bladder or detrusor overactivity, is the major cause of renal deterioration(13).In 
addition, older patients and those with a longer duration since SCI have a 
substantially higher risk for urological complications(14). At late stage post SCI, a 
high probability of change in the bladder management methods was reported 
indicating the importance of long-term planning from the time of SCI to minimize late 
complications(14). Indeed, since neuro-urological management evolved from reflex 
voiding and indwelling catheters to the widespread use of regular urodynamics, ISC, 
and antimuscarinics, optimized bladder management significantly contributed to the 
improved outcomes in SCI patients(15-17) with an enormous decrease of morbidity 
and mortality due to urological complications(2, 4, 5, 14).This is in line with the 
present longitudinal study showing urodynamic findings mostly within the normal 
range.  
Most of our patients underwent regular BoNTA intra detrusor injections and/or were 
on antimuscarinics(18). Antimuscarinics are the pharmacological first-line treatment 
for overactive bladder and all currently used antimuscarinics have well-established 
efficacy shown in systematic reviews(8, 19, 20), Although BoNTA injections into the 
detrusor have become a popular, well-accepted second-line treatment with a recent 
FDA approval in August 2011 for refractory neurogenic detrusor overactivity 
incontinence(21, 22), several important issues such as optimal dosage and injection 
technique, timing for repeat injection, short- and long-term safety, and exact 







Implications for practice 
Our treatment strategy is based on urodynamic findings and this is supported by a 
retrospective study of 80 SCI patients reporting that only urodynamic measurements 
are reliable to prevent upper urinary tract deterioration, since bladder function is 
unpredictable by other parameters(7).Based on the pattern of dysfunction, a 
therapeutic strategy should aim to preserve both upper and lower urinary tract 
function and to attain urinary continence. This can be achieved in patients with 
detrusor overactivity and detrusor sphincter dyssynergia by converting the overactive 
into an underactive detrusor by antimuscarinics and to assist or accomplish bladder 
emptying by ISC. If this cannot be achieved by antimuscarinics, BoNTA intra detrusor 
injections or rarely bladder augmentation or urinary diversion are considered. In 
patients with underactive/ acontractile detrusor and detrusor sphincter dyssynergia 
ISC is recommended. If some patients are not able and/or not willing to perform ISC 
an indwelling transurethral or suprapubic catheter should be used instead of  passive 
voiding by abdominal straining (Valsalva maneuver) or by suprapubic downwards 
compression of the lower abdomen (Credé maneuver).This creates unphysiologically 
high intravesical pressures which put the upper urinary tract at risk and also cause 
compression of the urethra, i.e. a functional obstruction leading to inefficient 
emptying. Thus, in accordance with the literature(16, 24-26), most of our patients 
relied on ISC. Recently, several authors(15, 27) found the suprapubic catheter a 
valuable treatment option in SCI patients. Although there is a lack of high-evidence 
level studies, we also support this view and prefer a suprapubic instead of a 
transurethral catheter. In the case of stress urinary incontinence due to decreased 
bladder outlet resistance, electrostimulation of the pelvic floor musculature may help 
to restore urinary continence in patients with incomplete lesions. In most patients with 
neurogenic stress urinary incontinence, however, the implantation of a suburethral 
sling or an artificial urinary sphincter may be necessary although this was not the 
case in the present study. Generally, artificial urinary sphincters are associated with a 
high revision rate but in SCI patients the modified “Nottwil technique” has been 
shown to be highly successful, reliable, safe, and even cost-effective(28). 
 
Implications for research 
Despite the management of NLUTD improved dramatically resulting in a substantial 
decrease of morbidity and mortality in SCI patients, many important issues remain to 
be elucidated. Thus, the patho-mechanisms involved in NLUTD are still incompletely 
understood. Indeed, SCI is not a stable chronic disease and modification of bladder 
management was necessary in more than one fourth of 196 SCI patients followed 
prospectively for 6 years(14). Electrophysiological and structural / biochemical 
changes during the long-term course of SCI patients may provide new insights into 
NLUTD warranting appropriately designed longitudinal studies applying a holistic 
approach, i.e. clinical, urodynamical, electrophysiological, structural/biochemical, and 
neuro-radiological assessments. Developing biomarkers for SCI patients guiding 
assessment, treatment and surveillance of NLUTD would be of great interest and 
could completely revolutionize modern neuro-urology. Nerve growth factor may 
become a clinically important biomarker and preliminary findings are promising(29). 
In addition, currently available treatment options need to be improved and new 
therapeutic targets have to be identified. Sacral neuromodulation(30) is a promising 
therapy but efficacy and safety have to be proven in randomized trials before more 




Limitations of the study 
Several limitations of the present study should be addressed. First, our study was not 
randomized and additional partly retrospective. Although it was longitudinal and the 
data of the current examination was gathered prospectively since 2010, the Data of 
the eldest examination had to be obtained retrospectively.  Second, quality of life was 
not systematically assessed and could therefore not be evaluated. However, based 
on this study’s findings, we introduced the Qualiveen questionnaire(32) in our routine 
neuro-urological work-up. Third, our patients underwent regular urinary tract 
ultrasound and video-urodynamics but not routine creatinine clearance and/or 
nuclear renal scan. It should be considered, however, that creatinine clearance has 
little value as a screening measure for renal disease in SCI patients because of its 
variability in serial testing(33). In addition, in the case of sonographically normal renal 
parenchyma and no VUR in the video-urodynamic investigation, the value of a 
nuclear renal scan is unclear. In fact, there is no generally agreed diagnostic 






Most of our regularly followed patients suffering from NLUTD due to SCI for a mean 
of 17years had normal maximum cystometric capacity, maximum detrusor pressure 
during the storage phase, and bladder compliance. VUR was quite rare and low 
grade. Thus, regular follow-up with urodynamic investigation allowing for individual 
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Table 1. Patient characteristics 





































Table 2. Type of bladder emptying according to lesion level 
 
 















Cervical 18 (14%) 19 (13%) 
Thoracic 75 (59%) 93 (64%) 
Lumbar 29 (23%) 29 (20%) 
Sacral 6 (5%) 4 (3%) 
Spontaneous voiding 75 (30%) 52 (21%) 
Cervical I 20(27%) 18 (35%) 
Thoracic II 40 (53%) 19 (37%) 
Lumbar III 14 (19%) 12 (23%) 
Sacral 1 (1%) 3 (6%) 
Indwelling catheter 43 (18%) 49 (20%) 
Cervical 16 (37%) 16 (33%) 
Thoracic 23 (54%) 27 (55%) 
Lumbar 4 (9%) 6 (12%) 
Sacral - - 
 
Iincluding 8 and 5 patients relying on a condom catheter at earliest and latest available 
urodynamic investigation, respectively 
IIincluding 14 and 2 patients relying on a condom catheter at earliest and latest available 
urodynamic investigation, respectively 
IIIincluding 2 and 1 patients relying on a condom catheter at earliest and latest available 







Table 3. Neuro-urological medication according to lesion level 
 
 















Cervical 33 (21%) 28 (21%) 
Thoracic 86 (55%) 69 (53%) 
Lumbar 32 (20%) 28 (21%) 
Sacral 7 (4%) 6 (5%) 
Alpha-blockers 5 (2%) 5 (2%) 
Cervical 1 (20%) 1 (20%) 
Thoracic 3 (60%) 2 (40%) 
Lumbar 1 (20%) 2 (40%) 
Sacral - - 
Antimuscarinics 53 (22%) 28 (11%) 
CervicalI 9 (17%) 4 (14%)  
ThoracicII 34 (64%) 18 (64%) 
LumbarIII 10 (19%) 5 (18%) 
Sacral - 1 (4%) 
OnabotulinumtoxinA injections 
into detrusor 
30 (12%) 82 (33%) 
Cervical IV 11 (37%) 21 (25%) 
Thoracic V 15 (50%) 49 (60%) 
LumbarVI 4 (13%) 12 (15%) 
Sacral - - 
 
Iincluding 2 and 0 patients takingaddition an a alpha-blockerat earliest and latest available 
urodynamic investigation, respectively 
IIincluding 1 and 2 patients takingaddition an a alpha-blocker at earliest and latest available 
urodynamic investigation, respectively 
IIIincluding 1 and 2 patients takingaddition an a alpha-blocker at earliest and latest available 
urodynamic investigation, respectively 
IVincluding 6 and 7 patients takingaddition an aantimuscarinic drug at earliest and latest 
available urodynamic investigation, respectively 
Vincluding 4 and 9 patients takingaddition an aantimuscarinic drug at earliest and latest 
available urodynamic investigation, respectively 
VIincluding 2 and 0 patients takingaddition an aantimuscarinic drug at earliest and latest 






Table 4. Video-urodynamic findings 
  












 Maximum cystometric capacity in mL 
(mean ± SD) 
 
440 ± 180 
 
650 ± 355 
 
<0.0001 
Compliance in mL/cmH2O (mean ± SD) 
 
55 ± 40 
 
95 ± 88 
 
<0.0001 
Maximum detrusor pressure during 
storage phase in cmH2O (mean ± SD) 
25 ± 17 34 ± 27 0.008 
Detrusor overactivity 59 (24%) 130 (53%) <0.0001 
- with incontinence  32 (13%) 56 (23%)  
- detrusor leak point pressure in   
cmH2O (mean ± SD)        49± 23 32 ± 25  
Detrusor sphincter dyssynergia 72 (30%) 61 (25%) 0.001 
Vesico-uretero-renal reflux 11 (4%)I 12 (5%)II 0.99 
- Grad 1-3 11 (4%) 11 (4%)  
- Grad 4-5 0 (0%) 1 (0%)  
 
IIncluding2 patients (1%) with bilateral reflux 
IIIncluding 7 patients (3%) with bilateral reflux 
 
 
